Minerva Neurosciences, Inc. (NERV)
- Previous Close
2.4700 - Open
2.4900 - Bid 1.8000 x 200
- Ask 3.2000 x 100
- Day's Range
2.3901 - 2.5200 - 52 Week Range
2.2590 - 13.4900 - Volume
14,113 - Avg. Volume
121,574 - Market Cap (intraday)
17.484M - Beta (5Y Monthly) 0.22
- PE Ratio (TTM)
-- - EPS (TTM)
-4.6100 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
www.minervaneurosciences.comRecent News: NERV
Performance Overview: NERV
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NERV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NERV
Valuation Measures
Market Cap
17.48M
Enterprise Value
-23.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
1.08
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.81%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-30.01M
Diluted EPS (ttm)
-4.6100
Balance Sheet and Cash Flow
Total Cash (mrq)
40.91M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.69M
Research Analysis: NERV
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell